Hemay-020 is under clinical development by Tianjin Hemay Pharmaceutical and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Hemay-020’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Hemay-020 overview

Hemay-020 is under development for the treatment of advanced solid cancer and advanced or metastatic non-small cell lung cancer. It is administered through the oral route. The drug candidate acts by targeting the epidermal growth factor receptor (EGFR). It is a new chemical entity.

Tianjin Hemay Pharmaceutical overview

Tianjin Hemay Pharmaceutical (Hemay) discovers, develops and commercializes novel drugs to treat tumors and immune diseases. The company is investigating preclinical programs including Hemay102, a cyrotoxic anticancer agent targeting hepatocellular carcinoma (HCC); Hemay022, a tyrosine kinase irreversible inhibitor for the treatment of breast cancer; Hemay020, a tyrosince kinase irreversible inhibitor against non-small cell lung cancer (NSCLC); Hemay007, an immunomodulatory agent for Inflammatory Bowel Disease (IBD); and Hemay005, a PDE4 inhibitor to treat psoriasis. It is also evaluating Hemay805, a cytokine inhibitor for influenza, SARS, swine influenza and avian influenza. Hemay has research and development, operations and industrialization centers in Tianjin, Jiangxi, China; Australia and the US. Hemay is headquartered in Tianjin, China.

For a complete picture of Hemay-020’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.